The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:
1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event.
Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
18 years of age or older
Informed consent
Deep vein thrombosis confirmed on ultrasonography OR
Pulmonary embolism confirmed on computed tomography angiography (CTA)
<18 years of age
no informed consent
Known haematological disorders
Active haematological malignancy
Participants will be recruited at Aarhus University Hospital at the department of Cardiology (AMI, VTE), Neurology (Stroke) and Radiology (VTE) and at the Blood Bank (Healthy volunteers).
Cohort
Prospective
Not listed
Platelet levels of heat shock protein 47 (HSP47) in patients with thrombosis compared to healthy controls
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Changes in platelet levels of HSP47 over time in patients with thrombosis
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry.
Platelet levels of HSP47 in association to platelet function
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Platelet function will be assessed by platelet aggregation and activation using impedance aggregometry and flow cytometry.
Platelet levels of HSP47 in association to fibrinolytic capacity
The level of HSP47 on platelets will be measured in a bloodsample. It will be measured using proteomics and flow cytometry. Fibrinolytic capacity will be assessed by ROTEM (R) tPA methods established in our lab, and by plasma fibrinolysis analyses.
Click on the lead sponsor to view all of their trials.
University of Aarhus
Lead sponsor
Aarhus University Hospital
Collaborator
Max Planck Institute of Biochemistry
Collaborator
Deutsches Herzzentrum der Charité, Berlin
Collaborator
